{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T01:28:29.102275+00:00","company":{"ticker":"CYCN","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"material_agreement","fact_key":"22fb20539ebec352f05f6c8f515d8fc14750b49e","cik":1755237,"ticker":"CYCN","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2026-04-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement and Plan of Merger and Reorganization","agreement_type":"merger","counterparty":"Korsana Biosciences, Inc.","effective_date":"2026-04-01","item_codes_triggered":["1.01"],"value_text":null},"claim":"Cyclerion Therapeutics, Inc. entered into Agreement and Plan of Merger and Reorganization with Korsana Biosciences, Inc. (effective 2026-04-01).","evidence_excerpt":"On April 1, 2026, Cyclerion Therapeutics, Inc., a Massachusetts corporation (“ Cyclerion ”), Cariboos Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Cyclerion (“ First Merger Sub ”), Cariboos Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Cyclerion (“ Second Merger Sub ” and, together with First Merger Sub, “ Merger Sub ”), and Korsana Biosciences, Inc., a Delaware corporation (“ Korsana ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-137909","anchor_url":"https://secwatch.observer/filing/0001193125-26-137909#claim-22fb20539ebec352f05f6c8f515d8fc14750b49e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1755237/000119312526137909/0001193125-26-137909-index.htm"},{"fact_type":"material_agreement","fact_key":"a250d70b9809bb5e5d89cafc400ee6b7aedd1f03","cik":1755237,"ticker":"CYCN","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2026-01-06T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Collaboration and Option Agreement","agreement_type":"collaboration","counterparty":"Medsteer, SAS","effective_date":"2026-01-03","item_codes_triggered":["1.01"],"value_text":"up to $3.7 million"},"claim":"Cyclerion Therapeutics, Inc. entered into Collaboration and Option Agreement with Medsteer, SAS valued at up to $3.7 million (effective 2026-01-03).","evidence_excerpt":"On January 3, 2026, Cyclerion Therapeutics, Inc. (the “Company”) and the Medsteer, SAS (“Medsteer”) entered into a Collaboration and Option Agreement (the “Collaboration Agreement”) pursuant to which Medsteer granted to the Company (i) a non-exclusive, worldwide, royalty-free, sublicensable license of certain of Medsteer’s technology, software and intellectual property to develop an anesthetic delivery system with Medsteer","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-003509","anchor_url":"https://secwatch.observer/filing/0001193125-26-003509#claim-a250d70b9809bb5e5d89cafc400ee6b7aedd1f03","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1755237/000119312526003509/0001193125-26-003509-index.htm"}]}